Cucurbitacin IIa: a novel class of anti-cancer drug inducing non-reversible actin aggregation and inhibiting survivin independent of JAK2/STAT3 phosphorylation

Mostrar otras versiones (1)

BACKGROUND: Cucurbitacin (Cuc) and triterpene-derived natural products exhibit anti-cancer potential in addition to their conspicuous anti-bacterial and anti-inflammatory activity. Recently, inhibition of Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling was...

Descripción completa

Detalles Bibliográficos
Autores principales: Boykin, C, Zhang, G, Chen, Y-H, Zhang, R-W, Fan, X-E, Yang, W-M, Lu, Q
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3048206/
https://www.ncbi.nlm.nih.gov/pubmed/21304528
http://dx.doi.org/10.1038/bjc.2011.10

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3048206/
https://www.ncbi.nlm.nih.gov/pubmed/21304528
http://dx.doi.org/10.1038/bjc.2011.10

Ejemplares similares